CrunchBase is hiring! Check out our open positions →
Register | Login or Login

General Information

Websitenlvpartners.com
Phone212-213-0006, ext. 27
Emailinfo@nlvpartners.com
Employees
Founded2005
DescriptionHealth-Care Focused VC Firm

Funds

Life Sciences Fund, 10/07 $450M

Offices

New York City
Times Square Tower
7 Times Square, Suite 3502
New York, NY, 10036
USA
Menlo Park
2500 Sand Hill Road
Suite 203
Menlo Park, CA, 94025
USA

People

Venture Partner
Managing Director
Public Investment Director

Tags

New Leaf Venture Partners

New Leaf Venture Partners is a venture capital firm that invests primarily in healthcare technology. The company typically focuses on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.

The New Leaf Ventures (NLV) team has been built over a decade, originating within Sprout Group, the venture capital affiliate of Credit Suisse First Boston. Sprout Group was formed in 1969 and has historically been one of the leading venture capital firms in the country. The team started to invest in healthcare technology in 1993 and since then, has become a leading venture investor in that sector. In 2005, the entire healthcare technology team of Sprout spun out into NLV.

Recent Milestones

Investments

Company Date Round Size Participants
Treato 4/13Series B$14.5M3
iRhythm Technologies 4/13Series D$16M4
Aviir 2/13Series F$10M4
Versartis 1/13Series C$25M4
Pearl Therapeutics 11/12Series D$65M4
Advanced Cell Diagnostics 11/12Series B$12M2
Principia BioPharma 10/12Series A$12.5M5
ReShape Medical 10/12Series C$15M3
IlluminOss Medical 9/12Series C$28M9
Karus Therapeutics 9/12Series B$7.6M4
Oxford Immunotec 6/12Venture Round$28M8
Awarepoint 6/12Venture Round$14M7
BioRelix 3/12Venture Round$2.56M4
Truveris 2/12Series B$10M4
Aviir 12/11Series E$10M4
CardioKinetix 9/11Series E$44M4
Neuronetics 5/11Series E$30M8
iRhythm Technologies 5/11Series C$15M3
Synageva BioPharma 3/11Venture Round$25M4
Versartis 2/11Series B$21M3
Chimerix 2/11Series F$45M8
Spine Wave 2/11Series E$17.5M5
Spiracur 2/11Venture Round$35M5
WorldHeart 10/10Venture Round$25.3M3
Pearl Therapeutics 10/10Series C$69M3
Convergence Pharmaceuticals 10/10Series A$35.4M3
Relypsa 9/10Series B$70M6
Intarcia Therapeutics 9/10Series B$5M3
Artisan Pharma 7/10Series C$3M5
Altura Medical 6/10Series A$20M3
Oxford Immunotec 5/10Series D$26M7
Aureon Laboratories 4/10Series D$7M4
Pearl Therapeutics 3/10Series C$15M3
Tioga Pharmaceuticals 2/10Series A$18M4
Aviir 1/10Debt$4.2M3
Afferent Pharmaceuticals 12/09Series A$23M4
Neuronetics 10/09Series D$30M7
Synageva BioPharma 10/09Series F$12M5
XDx 10/09Venture Round$14.4M7
Direct Flow Medical 10/09Series C$40M7
Presidio Pharmaceuticals 7/09Venture Round$27M1
Interlace Medical 7/09Series C$20M3
Spiracur 6/09Series B$20.3M3
VaxInnate 6/09Series D$30M7
Visiogen 5/09Series D$40M7
ReShape Medical 2/09Series B$20M3
Pearl Therapeutics 7/08Series A$18M4
Concert Pharmaceuticals 4/08Series C$37M12
Stromedix 4/08Series B$25M5
Oriel Therapeutics 11/07Venture Round$26.5M1
Relypsa 10/07Series A$33M6
Aviir 10/07Series B$11.3M3
ReShape Medical 8/07Series A$3M2
BioRelix 6/07Series A$25.8M6
Intarcia Therapeutics 3/07Series A5
Transcept Pharmaceuticals 3/07Series D$40M8
Concert Pharmaceuticals 11/06Series B$48.5M8
VaxInnate 10/06Series C$40M6
Artisan Pharma 9/06Series A$39M5
Tioga Pharmaceuticals 1/06Series A$24M3

Videos

Sources

  1. New Leaf raises $450M life-sciences fund (deals.venturebeat.com) [edit]
  2. Treato Raises $14.5m from OrbiMed, New Leaf and Reed Elsevier (prweb.com) [edit]
  3. iRhythm Technologies Closes $16M Series D Venture Financing (finsmes.com) [edit]
  4. Aviir Seals Agreement for Up to $30M in Funding (pehub.com) [edit]
  5. Versartis pockets $25M C round as it looks to PhII growth hormone study (fiercebiotech.com) [edit]
  6. Pearl Therapeutics Raises $65M in Series D Financing (finsmes.com) [edit]
  7. Advanced Cell Diagnostics Completes $12 Million Series B Financing (finance.yahoo.com) [edit]
  8. Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team (bizjournals.com) [edit]
  9. Obesity-Device Maker ReShape Medical Raises More Than $15M of $20M Series C (pevc.dowjones.com) [edit]
  10. IlluminOss Medical Secures $28 Million Series C Financing for Minimally Invasive Bone Fracture Repair (marketwire.com) [edit]
  11. Karus Thera Picks Up $7.6M to Develop Two Preclinical Compounds (pevc.dowjones.com) [edit]
  12. Oxford Immunotec Raises $28M in Equity Financing (finsmes.com) [edit]
  13. Awarepoint Tracks $14M for Hospital Workflow-Management Technology (pevc.dowjones.com) [edit]
  14. Connecticut biotech raises $2.56M round (masshightech.com) [edit]
  15. Truveris Closes $10M Series B Venture Funding (finsmes.com) [edit]
  16. Aviir, Inc.: Series E $10M (onbiovc.com) [edit]
  17. CardioKinetix Raises $44M in Series E Financing (finsmes.com) [edit]
  18. Neuronetics, Inc. Raises $30 Million in Series E Financing (marketwire.com) [edit]
  19. iRhythm Technologies, Inc. Raises $15 Million Series C Equity Round (irhythmtech.com) [edit]
  20. Synageva finds $25M financing for enzyme treatment (masshightech.com) [edit]
  21. Versartis Completes $21 Million Series B Financing (versartis.com) [edit]
  22. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157 (chimerix-inc.com) [edit]
  23. Spine Wave rounds up $17.5M financing (masshightech.com) [edit]
  24. Spiracur Closes $35M Equity Financing (finsmes.com) [edit]
  25. World Heart Corp. Completes Private Placement of $25.3 Million (finance.yahoo.com) [edit]
  26. Pearl lands $69M Series C for mid-stage COPD program (fiercebiotech.com) [edit]
  27. Convergence Pharmaceuticals Raises $35.4M in Series A Financing (finsmes.com) [edit]
  28. Relypsa Raises $70M in Series B Financing (finsmes.com) [edit]
  29. Intarcia Therapeutics raises $5M to treat long-term conditions (deals.venturebeat.com) [edit]
  30. Artisan Pharma adds $3M to coffers in new round (masshightech.com) [edit]
  31. Altura Medical, Inc.: Series A $20M (onbiovc.com) [edit]
  32. Oxford Immunotec, Ltd.: Series D $26M (onbiovc.com) [edit]
  33. onbiovc.com [edit]
  34. Pearl Therapeutics, Inc.: Series C $15M (onbiovc.com) [edit]
  35. Tioga Pharmaceuticals, Inc. Raises $18 Million to Fund Phase 3 Clinical Trial in Irritable Bowel Syndrome (tiogapharma.com) [edit]
  36. Aviir diagnoses heart conditions with new $4.2M (deals.venturebeat.com) [edit]
  37. Afferent Pharmaceuticals Closes $23M Series A Financing Round (finsmes.com) [edit]
  38. Neuronetics, Inc.: Series D $30M (onbiovc.com) [edit]
  39. Synageva attracts additional $12m to venture funding round (altassets.net) [edit]
  40. XDx, Inc.: Series G $14.4M (onbiovc.com) [edit]
  41. Direct Flow Medical takes $40M for heart valve treatments (deals.venturebeat.com) [edit]
  42. Presidio rounds up $27M for clinical studies (fiercebiotech.com) [edit]
  43. Interlace Medical, Inc.: Series C $20M (onbiovc.com) [edit]
  44. Spiracur, Inc.: Series B $20.3M (onbiovc.com) [edit]
  45. VaxInnate Corp., Series D $30M (onbiovc.com) [edit]
  46. Visiogen, Inc.: Series D $40M (onbiovc.com) [edit]
  47. ReShape beefs up with $20M to bust fat (deals.venturebeat.com) [edit]
  48. Pearl Therapeutics ups its first round funding (deals.venturebeat.com) [edit]
  49. Capital Funding Report [edit]
  50. Capital Funding Report [edit]
  51. Venture Capitalists Invest $26.5M in Oriel Therapeutics (ncbiotech.org) [edit]
  52. Amgen, Relypsa and the art of the biotech-spinout-startup-restart (venturebeat.com) [edit]
  53. Heart-diagnostic maker Aviir raises $11.3M (venturebeat.com) [edit]
  54. ReShape Medical Secures $3 Million in Series A Financing (researchviews.com) [edit]
  55. Nutmeg State biotech lands $25.8M in round one (masshightech.com) [edit]
  56. Intarcia restarts with $50M for hepatitis, diabetes treatments (deals.venturebeat.com) [edit]
  57. Insomnia drug company, TransOral, raises $40M more (deals.venturebeat.com) [edit]
  58. Concert Pharmaceuticals Raises $48.5 Million in Series B Financing (concertpharma.com) [edit]
  59. VaxInnate Secures $40 Million Series C Financing. (thefreelibrary.com) [edit]
  60. Artisan Pharma, Inc. Raises $39 Million in a Series A Financing Led by NGN Capital LLC (artisanpharma.net) [edit]
  61. Tioga’s Series A Round: $24M For Phase IIb Trial Of IBS Drug (tiogapharma.com) [edit]
Edit This Page
Last Edited 5/21/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

Recent Incoming Links

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy